As described above, although IFN-α2b and high dose IL-2 therapy showed potential in improving prognosis in earlier clinical trials, many melanoma patients were unable to continue these treatments due to severe toxicities, such as fatigue, fevers, arthralgias, liver function abnormalities, neutropenia, and nausea [17]. The gene discussed is IL2; the disease is melanoma.